Login Register Cart 0
Generic placeholder image

Current Neuropharmacology

Editor-in-Chief

ISSN (Print): 1570-159X
ISSN (Online): 1875-6190

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Drug Choices and Advancements for Managing Depression in Parkinson's Disease

Author(s): Francesca Assogna, Clelia Pellicano, Cinzia Savini, Lucia Macchiusi, Gaia R. Pellicano, Marika Alborghetti, Carlo Caltagirone, Gianfranco Spalletta and Francesco E. Pontieri*

Volume 18, Issue 4, 2020

Page: [277 - 287] Pages: 11

DOI: 10.2174/1570159X17666191016094857

Price: $65

Abstract

Depression is a frequent non-motor symptom of Parkinson’s disease (PD), and may even precede the onset of motor symptoms of parkinsonism. Beyond its negative influence on mood, depression in PD is frequently associated with other neuropsychiatric symptoms and with late-stage complications such as dementia. Despite its profound impact on the quality of life and cognitive functioning in PD, depression in PD is often under-recognized and poorly treated.

Pathophysiological studies demonstrated that depression in PD is associated with global dysfunction of interactions between discrete brain areas rather than focal structural or functional abnormalities, and that it is sustained by pathological changes of several neurotransmitter/receptor complexes.

In general, all traditional antidepressants and some dopamine agonists have been found to be safe and well-tolerated to treat depressive symptoms in PD, despite initial warning on worsening of parkinsonism. Available data suggest that the time-course of response differs among antidepressants. Efficacy results from clinical trials with antidepressant in PD are, however, rather uncertain, although pooled analysis suggests a moderate benefit. Several issues may critically impact the results of clinical trials with antidepressants in PD, including the correct psychiatric diagnosis, the overlap of symptoms between depression and PD, and the selection of appropriate end-points and rating scales.

Keywords: Antidepressants, depression, non-motor symptoms, Parkinson's disease, quality of life, affective disorders.

« Previous Next »
Graphical Abstract

[1]
Titova, N.; Padmakumar, C.; Lewis, S.J.G.; Chaudhuri, K.R. Parkinson’s: A syndrome rather than a disease? J. Neural Transm. (Vienna), 2017, 124(8), 907-914.
[http://dx.doi.org/10.1007/s00702-016-1667-6] [PMID: 28028643]
[2]
Braak, H.; Rüb, U.; Gai, W.P.; Del Tredici, K. Idiopathic Parkinson’s disease: Possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J. Neural Transm. (Vienna), 2003, 110(5), 517-536.
[http://dx.doi.org/10.1007/s00702-002-0808-2] [PMID: 12721813]
[3]
Valappil, R.A.; Black, J.E.; Broderick, M.J.; Carrillo, O.; Frenette, E.; Sullivan, S.S.; Goldman, S.M.; Tanner, C.M.; Langston, J.W. Exploring the electrocardiogram as a potential tool to screen for premotor Parkinson’s disease. Mov. Disord., 2010, 25(14), 2296-2303.
[http://dx.doi.org/10.1002/mds.23348] [PMID: 20976736]
[4]
Schapira, A.H.V.; Chaudhuri, K.R.; Jenner, P. Non-motor features of Parkinson disease. Nat. Rev. Neurosci., 2017, 18(7), 435-450.
[http://dx.doi.org/10.1038/nrn.2017.62] [PMID: 28592904]
[5]
Pellicano, C.; Benincasa, D.; Pisani, V.; Buttarelli, F.R.; Giovannelli, M.; Pontieri, F.E. Prodromal non-motor symptoms of Parkinson’s disease. Neuropsychiatr. Dis. Treat., 2007, 3(1), 145-152.
[http://dx.doi.org/10.2147/nedt.2007.3.1.145] [PMID: 19300544]
[6]
Pfeiffer, R.F. Non-motor symptoms in Parkinson’s disease. Parkinsonism Relat. Disord., 2016, 22(Suppl. 1), S119-S122.
[http://dx.doi.org/10.1016/j.parkreldis.2015.09.004] [PMID: 26372623]
[7]
Yapici Eser, H.; Bora, H.A.; Kuruoğlu, A. Depression and Parkinson disease: Prevalence, temporal relationship, and determinants. Turk. J. Med. Sci., 2017, 47(2), 499-503.
[http://dx.doi.org/10.3906/sag-1603-101] [PMID: 28425238]
[8]
Starkstein, S.E.; Merello, M. Psychiatric and cognitive disorders in parkinson’s disease; Cambridge University Press, 2002.
[9]
Reijnders, J.S.; Ehrt, U.; Weber, W.E.; Aarsland, D.; Leentjens, A.F. A systematic review of prevalence studies of depression in Parkinson’s disease. Mov. Disord., 2008, 23(2), 183-189.
[http://dx.doi.org/10.1002/mds.21803] [PMID: 17987654]
[10]
Hoogendijk, W.J.; Sommer, I.E.; Tissingh, G.; Deeg, D.J.; Wolters, E.C. Depression in Parkinson’s disease. The impact of symptom overlap on prevalence. Psychosomatics, 1998, 39(5), 416-421.
[http://dx.doi.org/10.1016/S0033-3182(98)71300-3] [PMID: 9775698]
[11]
Barone, P.; Antonini, A.; Colosimo, C.; Marconi, R.; Morgante, L.; Avarello, T.P.; Bottacchi, E.; Cannas, A.; Ceravolo, G.; Ceravolo, R.; Cicarelli, G.; Gaglio, R.M.; Giglia, R.M.; Iemolo, F.; Manfredi, M.; Meco, G.; Nicoletti, A.; Pederzoli, M.; Petrone, A.; Pisani, A.; Pontieri, F.E.; Quatrale, R.; Ramat, S.; Scala, R.; Volpe, G.; Zappulla, S.; Bentivoglio, A.R.; Stocchi, F.; Trianni, G.; Dotto, P.D. The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov. Disord., 2009, 24(11), 1641-1649.
[http://dx.doi.org/10.1002/mds.22643] [PMID: 19514014]
[12]
Martinez-Martin, P.; Falup Pecurariu, C.; Odin, P.; van Hilten, J.J.; Antonini, A.; Rojo-Abuin, J.M.; Borges, V.; Trenkwalder, C.; Aarsland, D.; Brooks, D.J.; Ray Chaudhuri, K. Gender-related differences in the burden of non-motor symptoms in Parkinson’s disease. J. Neurol., 2012, 259(8), 1639-1647.
[http://dx.doi.org/10.1007/s00415-011-6392-3] [PMID: 22237822]
[13]
Guo, X.; Song, W.; Chen, K.; Chen, X.; Zheng, Z.; Cao, B.; Huang, R.; Zhao, B.; Wu, Y.; Shang, H-F. Gender and onset age-related features of non-motor symptoms of patients with Parkinson’s disease--a study from Southwest China. Parkinsonism Relat. Disord., 2013, 19(11), 961-965.
[http://dx.doi.org/10.1016/j.parkreldis.2013.06.009] [PMID: 23849500]
[14]
Nicoletti, A.; Vasta, R.; Mostile, G.; Nicoletti, G.; Arabia, G.; Iliceto, G.; Lamberti, P.; Marconi, R.; Morgante, L.; Barone, P.; Quattrone, A.; Zappia, M. Gender effect on non-motor symptoms in Parkinson’s disease: are men more at risk? Parkinsonism Relat. Disord., 2017, 35, 69-74.
[http://dx.doi.org/10.1016/j.parkreldis.2016.12.008] [PMID: 28017549]
[15]
Weintraub, D.; Moberg, P.J.; Duda, J.E.; Katz, I.R.; Stern, M.B. Effect of psychiatric and other nonmotor symptoms on disability in Parkinson’s disease. J. Am. Geriatr. Soc., 2004, 52(5), 784-788.
[http://dx.doi.org/10.1111/j.1532-5415.2004.52219.x] [PMID: 15086662]
[16]
Balestrino, R.; Martinez-Martin, P. Neuropsychiatric symptoms, behavioural disorders, and quality of life in Parkinson’s disease. J. Neurol. Sci., 2017, 373, 173-178.
[http://dx.doi.org/10.1016/j.jns.2016.12.060] [PMID: 28131182]
[17]
Shulman, L.M.; Taback, R.L.; Rabinstein, A.A.; Weiner, W.J. Non-recognition of depression and other non-motor symptoms in Parkinson’s disease. Parkinsonism Relat. Disord., 2002, 8(3), 193-197.
[http://dx.doi.org/10.1016/S1353-8020(01)00015-3] [PMID: 12039431]
[18]
Weintraub, D.; Moberg, P.J.; Duda, J.E.; Katz, I.R.; Stern, M.B. Recognition and treatment of depression in Parkinson’s disease. J. Geriatr. Psychiatry Neurol., 2003, 16(3), 178-183.
[http://dx.doi.org/10.1177/0891988703256053] [PMID: 12967062]
[19]
Pachana, N.A.; Egan, S.J.; Laidlaw, K.; Dissanayaka, N.; Byrne, G.J.; Brockman, S.; Marsh, R.; Starkstein, S. Clinical issues in the treatment of anxiety and depression in older adults with Parkinson’s disease. Mov. Disord., 2013, 28(14), 1930-1934.
[http://dx.doi.org/10.1002/mds.25689] [PMID: 24123116]
[20]
Menza, M.; Dobkin, R.D.; Marin, H.; Mark, M.H.; Gara, M.; Buyske, S.; Bienfait, K.; Dicke, A. The impact of treatment of depression on quality of life, disability and relapse in patients with Parkinson’s disease. Mov. Disord., 2009, 24(9), 1325-1332.
[http://dx.doi.org/10.1002/mds.22586] [PMID: 19412944]
[21]
Gold, M.S.; Blum, K.; Febo, M.; Baron, D.; Modestino, E.J.; Elman, I.; Badgaiyan, R.D. Molecular role of dopamine in anhedonia linked to reward deficiency syndrome (RDS) and anti- reward systems. Front. Biosci. (Schol. Ed.), 2018, 10, 309-325.
[http://dx.doi.org/10.2741/s518] [PMID: 29293435]
[22]
Blum, K.; Gondré-Lewis, M.C.; Baron, D.; Thanos, P.K.; Braverman, E.R.; Neary, J.; Elman, I.; Badgaiyan, R.D. Introducing precision addiction management of reward deficiency syndrome, the construct that underpins all addictive behaviors. Front. Psychiatry, 2018, 9, 548.
[http://dx.doi.org/10.3389/fpsyt.2018.00548] [PMID: 30542299]
[23]
Lim, E.W.; Tan, E.K. Genes and nonmotor symptoms in Parkinson’s disease. Int. Rev. Neurobiol., 2017, 133, 111-127.
[http://dx.doi.org/10.1016/bs.irn.2017.05.029] [PMID: 28802918]
[24]
Burn, D.J.; Tiangyou, W.; Allcock, L.M.; Davison, J.; Chinnery, P.F. Allelic variation of a functional polymorphism in the serotonin transporter gene and depression in Parkinson’s disease. Parkinsonism Relat. Disord., 2006, 12(3), 139-141.
[http://dx.doi.org/10.1016/j.parkreldis.2005.11.005] [PMID: 16459126]
[25]
Menza, M.A.; Palermo, B.; DiPaola, R.; Sage, J.I.; Ricketts, M.H. Depression and anxiety in Parkinson’s disease: possible effect of genetic variation in the serotonin transporter. J. Geriatr. Psychiatry Neurol., 1999, 12(2), 49-52.
[http://dx.doi.org/10.1177/089198879901200202] [PMID: 10483924]
[26]
Beavan, M.; McNeill, A.; Proukakis, C.; Hughes, D.A.; Mehta, A.; Schapira, A.H.V. Evolution of prodromal clinical markers of Parkinson disease in a GBA mutation-positive cohort. JAMA Neurol., 2015, 72(2), 201-208.
[http://dx.doi.org/10.1001/jamaneurol.2014.2950] [PMID: 25506732]
[27]
Dan, X.; Wang, C.; Zhang, J.; Gu, Z.; Zhou, Y.; Ma, J.; Chan, P. Association between common genetic risk variants and depression in Parkinson’s disease: A dPD study in Chinese. Parkinsonism Relat. Disord., 2016, 33, 122-126.
[http://dx.doi.org/10.1016/j.parkreldis.2016.09.029] [PMID: 27745782]
[28]
Kostić, V.S.; Agosta, F.; Petrović, I.; Galantucci, S.; Spica, V.; Jecmenica-Lukic, M.; Filippi, M. Regional patterns of brain tissue loss associated with depression in Parkinson disease. Neurology, 2010, 75(10), 857-863.
[http://dx.doi.org/10.1212/WNL.0b013e3181f11c1d] [PMID: 20686125]
[29]
Frosini, D.; Unti, E.; Guidoccio, F.; Del Gamba, C.; Puccini, G.; Volterrani, D.; Bonuccelli, U.; Ceravolo, R. Mesolimbic dopaminergic dysfunction in Parkinson’s disease depression: Evidence from a 123I-FP-CIT SPECT investigation. J. Neural Transm. (Vienna), 2015, 122(8), 1143-1147.
[http://dx.doi.org/10.1007/s00702-015-1370-z] [PMID: 25613061]
[30]
Wei, L.; Hu, X.; Yuan, Y.; Liu, W.; Chen, H. Abnormal ventral tegmental area-anterior cingulate cortex connectivity in Parkinson’s disease with depression. Behav. Brain Res., 2018, 347, 132-139.
[http://dx.doi.org/10.1016/j.bbr.2018.03.011] [PMID: 29530489]
[31]
Thobois, S.; Prange, S.; Sgambato-Faure, V.; Tremblay, L.; Broussolle, E. Imaging the etiology of apathy, anxiety, and depression in Parkinson’s disease: Implication for treatment. Curr. Neurol. Neurosci. Rep., 2017, 17(10), 76.
[http://dx.doi.org/10.1007/s11910-017-0788-0] [PMID: 28822071]
[32]
Remy, P.; Doder, M.; Lees, A.; Turjanski, N.; Brooks, D. Depression in Parkinson’s disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain, 2005, 128(Pt 6), 1314-1322.
[http://dx.doi.org/10.1093/brain/awh445] [PMID: 15716302]
[33]
Felicio, A.C.; Moriyama, T.S.; Godeiro-Junior, C.; Shih, M.C.; Hoexter, M.Q.; Borges, V.; Silva, S.M.; Amaro-Junior, E.; Andrade, L.A.; Ferraz, H.B.; Bressan, R.A. Higher dopamine transporter density in Parkinson’s disease patients with depression. Psychopharmacology (Berl.), 2010, 211(1), 27-31.
[http://dx.doi.org/10.1007/s00213-010-1867-y] [PMID: 20495790]
[34]
Stark, A.J.; Smith, C.T.; Petersen, K.J.; Trujillo, P.; van Wouwe, N.C.; Donahue, M.J.; Kessler, R.M.; Deutch, A.Y.; Zald, D.H.; Claassen, D.O. [18F]fallypride characterization of striatal and extrastriatal D2/3 receptors in Parkinson’s disease. Neuroimage Clin., 2018, 18, 433-442.
[http://dx.doi.org/10.1016/j.nicl.2018.02.010] [PMID: 29541577]
[35]
Politis, M.; Wu, K.; Loane, C.; Turkheimer, F.E.; Molloy, S.; Brooks, D.J.; Piccini, P. Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures. Neurology, 2010, 75(21), 1920-1927.
[http://dx.doi.org/10.1212/WNL.0b013e3181feb2ab] [PMID: 21098407]
[36]
Maillet, A.; Krack, P.; Lhommée, E.; Météreau, E.; Klinger, H.; Favre, E.; Le Bars, D.; Schmitt, E.; Bichon, A.; Pelissier, P.; Fraix, V.; Castrioto, A.; Sgambato-Faure, V.; Broussolle, E.; Tremblay, L.; Thobois, S. The prominent role of serotonergic degeneration in apathy, anxiety and depression in de novo Parkinson’s disease. Brain, 2016, 139(Pt 9), 2486-2502.
[http://dx.doi.org/10.1093/brain/aww162] [PMID: 27538418]
[37]
Boileau, I.; Warsh, J.J.; Guttman, M.; Saint-Cyr, J.A.; McCluskey, T.; Rusjan, P.; Houle, S.; Wilson, A.A.; Meyer, J.H.; Kish, S.J. Elevated serotonin transporter binding in depressed patients with Parkinson’s disease: A preliminary PET study with [11C]DASB. Mov. Disord., 2008, 23(12), 1776-1780.
[http://dx.doi.org/10.1002/mds.22212] [PMID: 18661545]
[38]
Ballanger, B.; Klinger, H.; Eche, J.; Lerond, J.; Vallet, A.E.; Le Bars, D.; Tremblay, L.; Sgambato-Faure, V.; Broussolle, E.; Thobois, S. Role of serotonergic 1A receptor dysfunction in depression associated with Parkinson’s disease. Mov. Disord., 2012, 27(1), 84-89.
[http://dx.doi.org/10.1002/mds.23895] [PMID: 21994070]
[39]
Pasquini, J.; Ceravolo, R.; Brooks, D.J.; Bonuccelli, U.; Pavese, N. Progressive loss of raphe nuclei serotonin transporter in early Parkinson's disease: A longitudinal 123I-FP-CIT SPECT study. Parkinsonism Relat Disord.,, 2019, S1353-8020(19), 30185-3.
[40]
Mayberg, H.S.; Starkstein, S.E.; Sadzot, B.; Preziosi, T.; Andrezejewski, P.L.; Dannals, R.F.; Wagner, H.N., Jr; Robinson, R.G. Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson’s disease. Ann. Neurol., 1990, 28(1), 57-64.
[http://dx.doi.org/10.1002/ana.410280111] [PMID: 2375634]
[41]
Luo, C.; Song, W.; Chen, Q.; Yang, J.; Gong, Q.; Shang, H.F. Cortical thinning in drug-naive Parkinson’s disease patients with depression. J. Neurol., 2016, 263(10), 2114-2119.
[http://dx.doi.org/10.1007/s00415-016-8241-x] [PMID: 27485171]
[42]
Huang, P.; Xuan, M.; Gu, Q.; Yu, X.; Xu, X.; Luo, W.; Zhang, M. Abnormal amygdala function in Parkinson’s disease patients and its relationship to depression. J. Affect. Disord., 2015, 183, 263-268.
[http://dx.doi.org/10.1016/j.jad.2015.05.029] [PMID: 26042728]
[43]
Cardoso, E.F.; Maia, F.M.; Fregni, F.; Myczkowski, M.L.; Melo, L.M.; Sato, J.R.; Marcolin, M.A.; Rigonatti, S.P.; Cruz, A.C., Jr; Barbosa, E.R.; Amaro, E., Jr Depression in Parkinson’s disease: Convergence from voxel-based morphometry and functional magnetic resonance imaging in the limbic thalamus. Neuroimage, 2009, 47(2), 467-472.
[http://dx.doi.org/10.1016/j.neuroimage.2009.04.059] [PMID: 19398020]
[44]
Li, W.; Liu, J.; Skidmore, F.; Liu, Y.; Tian, J.; Li, K. White matter microstructure changes in the thalamus in Parkinson disease with depression: A diffusion tensor MR imaging study. AJNR Am. J. Neuroradiol., 2010, 31(10), 1861-1866.
[http://dx.doi.org/10.3174/ajnr.A2195] [PMID: 20705702]
[45]
Hu, X.; Song, X.; Yuan, Y.; Li, E.; Liu, J.; Liu, W.; Liu, Y. Abnormal functional connectivity of the amygdala is associated with depression in Parkinson’s disease. Mov. Disord., 2015, 30(2), 238-244.
[http://dx.doi.org/10.1002/mds.26087] [PMID: 25545969]
[46]
Kim, Y.D.; Jeong, H.S.; Song, I.U.; Chung, Y.A.; Namgung, E.; Kim, Y.D. Brain perfusion alterations in depressed patients with Parkinson’s disease. Ann. Nucl. Med., 2016, 30(10), 731-737.
[http://dx.doi.org/10.1007/s12149-016-1119-2] [PMID: 27566684]
[47]
Liang, P.; Deshpande, G.; Zhao, S.; Liu, J.; Hu, X.; Li, K. Altered directional connectivity between emotion network and motor network in Parkinson’s disease with depression. Medicine (Baltimore), 2016, 95(30)e4222
[http://dx.doi.org/10.1097/MD.0000000000004222] [PMID: 27472694]
[48]
Kerestes, R.; Davey, C.G.; Stephanou, K.; Whittle, S.; Harrison, B.J. Functional brain imaging studies of youth depression: A systematic review. Neuroimage Clin., 2013, 4, 209-231.
[http://dx.doi.org/10.1016/j.nicl.2013.11.009] [PMID: 24455472]
[49]
Feldmann, A.; Illes, Z.; Kosztolanyi, P.; Illes, E.; Mike, A.; Kover, F.; Balas, I.; Kovacs, N.; Nagy, F. Morphometric changes of gray matter in Parkinson’s disease with depression: A voxel-based morphometry study. Mov. Disord., 2008, 23(1), 42-46.
[http://dx.doi.org/10.1002/mds.21765] [PMID: 17973326]
[50]
Wen, X.; Wu, X.; Liu, J.; Li, K.; Yao, L. Abnormal baseline brain activity in non-depressed Parkinson’s disease and depressed Parkinson’s disease: A resting-state functional magnetic resonance imaging study. PLoS One, 2013, 8(5)e63691
[http://dx.doi.org/10.1371/journal.pone.0063691] [PMID: 23717467]
[51]
Luo, C.; Chen, Q.; Song, W.; Chen, K.; Guo, X.; Yang, J.; Huang, X.; Gong, Q.; Shang, H.F. Resting-state fMRI study on drug-naive patients with Parkinson’s disease and with depression. J. Neurol. Neurosurg. Psychiatry, 2014, 85(6), 675-683.
[http://dx.doi.org/10.1136/jnnp-2013-306237] [PMID: 24227759]
[52]
Starkstein, S.E.; Preziosi, T.J.; Forrester, A.W.; Robinson, R.G. Specificity of affective and autonomic symptoms of depression in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry, 1990, 53(10), 869-873.
[http://dx.doi.org/10.1136/jnnp.53.10.869] [PMID: 2266368]
[53]
Kostić, V.S.; Pekmezović, T.; Tomić, A.; Jecmenica-Lukić, M.; Stojković, T.; Spica, V.; Svetel, M.; Stefanova, E.; Petrović, I.; Dzoljić, E. Suicide and suicidal ideation in Parkinson’s disease. J. Neurol. Sci., 2010, 289(1-2), 40-43.
[http://dx.doi.org/10.1016/j.jns.2009.08.016] [PMID: 19737673]
[54]
Cummings, J.L. Depression and Parkinson’s disease: a review. Am. J. Psychiatry, 1992, 149(4), 443-454.
[http://dx.doi.org/10.1176/ajp.149.4.443] [PMID: 1372794]
[55]
Myslobodsky, M.; Lalonde, F.M.; Hicks, L. Are patients with Parkinson’s disease suicidal? J. Geriatr. Psychiatry Neurol., 2001, 14(3), 120-124.
[http://dx.doi.org/10.1177/089198870101400304] [PMID: 11563434]
[56]
Funkiewiez, A.; Ardouin, C.; Caputo, E.; Krack, P.; Fraix, V.; Klinger, H.; Chabardes, S.; Foote, K.; Benabid, A.L.; Pollak, P. Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry, 2004, 75(6), 834-839.
[http://dx.doi.org/10.1136/jnnp.2002.009803] [PMID: 15145995]
[57]
Storch, A.; Schneider, C.B.; Wolz, M.; Stürwald, Y.; Nebe, A.; Odin, P.; Mahler, A.; Fuchs, G.; Jost, W.H.; Chaudhuri, K.R.; Koch, R.; Reichmann, H.; Ebersbach, G. Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications. Neurology, 2013, 80(9), 800-809.
[http://dx.doi.org/10.1212/WNL.0b013e318285c0ed] [PMID: 23365054]
[58]
Bagby, R.M.; Parker, J.D.; Taylor, G.J. Dimensional analysis of the MMPI Alexithymia scale. J. Clin. Psychol., 1991, 47(2), 221-226.
[PMID: 2030127]
[59]
Assogna, F.; Palmer, K.; Pontieri, F.E.; Pierantozzi, M.; Stefani, A.; Gianni, W.; Caltagirone, C.; Spalletta, G. Alexithymia is a non-motor symptom of Parkinson disease. Am. J. Geriatr. Psychiatry, 2012, 20(2), 133-141.
[http://dx.doi.org/10.1097/JGP.0b013e318209de07] [PMID: 22273734]
[60]
Costa, A.; Peppe, A.; Carlesimo, G.A.; Pasqualetti, P.; Caltagirone, C. Alexithymia in Parkinson’s disease is related to severity of depressive symptoms. Eur. J. Neurol., 2006, 13(8), 836-841.
[http://dx.doi.org/10.1111/j.1468-1331.2006.01216.x] [PMID: 16879293]
[61]
Costa, A.; Peppe, A.; Carlesimo, G.A.; Salamone, G.; Caltagirone, C. Prevalence and characteristics of alexithymia in Parkinson’s disease. Psychosomatics, 2010, 51(1), 22-28.
[http://dx.doi.org/10.1016/S0033-3182(10)70655-1] [PMID: 20118437]
[62]
Poletti, M.; Frosini, D.; Pagni, C.; Lucetti, C.; Del Dotto, P.; Tognoni, G.; Ceravolo, R.; Bonuccelli, U. The association between motor subtypes and alexithymia in de novo Parkinson’s disease. J. Neurol., 2011, 258(6), 1042-1045.
[http://dx.doi.org/10.1007/s00415-010-5878-8] [PMID: 21188407]
[63]
Poletti, M.; De Rosa, A.; Bonuccelli, U. Affective symptoms and cognitive functions in Parkinson’s disease. J. Neurol. Sci., 2012, 317(1-2), 97-102.
[http://dx.doi.org/10.1016/j.jns.2012.02.022] [PMID: 22503136]
[64]
Kirsch-Darrow, L.; Fernandez, H.H.; Marsiske, M.; Okun, M.S.; Bowers, D. Dissociating apathy and depression in Parkinson disease. Neurology, 2006, 67(1), 33-38.
[http://dx.doi.org/10.1212/01.wnl.0000230572.07791.22] [PMID: 16832074]
[65]
Dujardin, K.; Sockeel, P.; Devos, D.; Delliaux, M.; Krystkowiak, P.; Destée, A.; Defebvre, L. Characteristics of apathy in Parkinson’s disease. Mov. Disord., 2007, 22(6), 778-784.
[http://dx.doi.org/10.1002/mds.21316] [PMID: 17290451]
[66]
Pedersen, K.F.; Alves, G.; Aarsland, D.; Larsen, J.P. Occurrence and risk factors for apathy in Parkinson disease: a 4-year prospective longitudinal study. J. Neurol. Neurosurg. Psychiatry, 2009, 80(11), 1279-1282.
[http://dx.doi.org/10.1136/jnnp.2008.170043] [PMID: 19864662]
[67]
Drijgers, R.L.; Dujardin, K.; Reijnders, J.S.; Defebvre, L.; Leentjens, A.F. Validation of diagnostic criteria for apathy in Parkinson’s disease. Parkinsonism Relat. Disord., 2010, 16(10), 656-660.
[http://dx.doi.org/10.1016/j.parkreldis.2010.08.015] [PMID: 20864380]
[68]
Aarsland, D.; Larsen, J.P.; Lim, N.G.; Janvin, C.; Karlsen, K.; Tandberg, E.; Cummings, J.L. Range of neuropsychiatric disturbances in patients with Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry, 1999, 67(4), 492-496.
[http://dx.doi.org/10.1136/jnnp.67.4.492] [PMID: 10486397]
[69]
Pluck, G.C.; Brown, R.G. Apathy in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry, 2002, 73(6), 636-642.
[http://dx.doi.org/10.1136/jnnp.73.6.636] [PMID: 12438462]
[70]
Isella, V.; Melzi, P.; Grimaldi, M.; Iurlaro, S.; Piolti, R.; Ferrarese, C.; Frattola, L.; Appollonio, I. Clinical, neuropsychological, and morphometric correlates of apathy in Parkinson’s disease. Mov. Disord., 2002, 17(2), 366-371.
[http://dx.doi.org/10.1002/mds.10041] [PMID: 11921125]
[71]
Snaith, R.P.; Hamilton, M.; Morley, S.; Humayan, A.; Hargreaves, D.; Trigwell, P. A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale. Br. J. Psychiatry, 1995, 167(1), 99-103.
[http://dx.doi.org/10.1192/bjp.167.1.99] [PMID: 7551619]
[72]
Lemke, MR; Fuchs, G; Gemende, I; Herting, B; Oehlwein, C; Reichmann, H; Rieke, J; Volkmann, J Depression and Parkinson's disease. J Neurol.,, 2004, 251(Suppl 6), VI/24-7.
[http://dx.doi.org/10.1007/s00415-004-1606-6] [PMID: 15675721]
[73]
Miura, S.; Kida, H.; Nakajima, J.; Noda, K.; Nagasato, K.; Ayabe, M.; Aizawa, H.; Hauser, M.; Taniwaki, T. Anhedonia in Japanese patients with Parkinson’s disease: Analysis using the Snaith-Hamilton pleasure scale. Clin. Neurol. Neurosurg., 2012, 114(4), 352-355.
[http://dx.doi.org/10.1016/j.clineuro.2011.11.008] [PMID: 22137783]
[74]
Lemke, M.R.; Brecht, H.M.; Koester, J.; Kraus, P.H.; Reichmann, H. Anhedonia, depression, and motor functioning in Parkinson’s disease during treatment with pramipexole. J. Neuropsychiatry Clin. Neurosci., 2005, 17(2), 214-220.
[http://dx.doi.org/10.1176/jnp.17.2.214] [PMID: 15939976]
[75]
Fujiwara, S.; Kimura, F.; Hosokawa, T.; Ishida, S.; Sugino, M.; Hanafusa, T. Anhedonia in Japanese patients with Parkinson’s disease. Geriatr. Gerontol. Int., 2011, 11(3), 275-281.
[http://dx.doi.org/10.1111/j.1447-0594.2010.00678.x] [PMID: 21241445]
[76]
Lemke, M.R.; Brecht, H.M.; Koester, J.; Reichmann, H. Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson’s disease. J. Neurol. Sci., 2006, 248(1-2), 266-270.
[http://dx.doi.org/10.1016/j.jns.2006.05.024] [PMID: 16814808]
[77]
Weintraub, D.; Mavandadi, S.; Mamikonyan, E.; Siderowf, A.D.; Duda, J.E.; Hurtig, H.I.; Colcher, A.; Horn, S.S.; Nazem, S.; Ten Have, T.R.; Stern, M.B. Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology, 2010, 75(5), 448-455.
[http://dx.doi.org/10.1212/WNL.0b013e3181ebdd79] [PMID: 20679638]
[78]
Costa, F.H.; Rosso, A.L.; Maultasch, H.; Nicaretta, D.H.; Vincent, M.B. Depression in Parkinson’s disease: diagnosis and treatment. Arq. Neuropsiquiatr., 2012, 70(8), 617-620.
[http://dx.doi.org/10.1590/S0004-282X2012000800011] [PMID: 22899034]
[79]
Bomasang-Layno, E.; Fadlon, I.; Murray, A.N.; Himelhoch, S. Antidepressive treatments for Parkinson’s disease: A systematic review and meta-analysis. Parkinsonism Relat. Disord., 2015, 21(8), 833-842.
[http://dx.doi.org/10.1016/j.parkreldis.2015.04.018] [PMID: 26037457]
[80]
Zhuo, C.; Xue, R.; Luo, L.; Ji, F.; Tian, H.; Qu, H.; Lin, X.; Jiang, R.; Tao, R. Efficacy of antidepressive medication for depression in Parkinson disease: a network meta-analysis. Medicine (Baltimore), 2017, 96(22)e6698
[http://dx.doi.org/10.1097/MD.0000000000006698] [PMID: 28562526]
[81]
Vanle, B.; Olcott, W.; Jimenez, J.; Bashmi, L.; Danovitch, I. IsHak, W.W. NMDA antagonists for treating the non-motor symptoms in Parkinson’s disease. Transl. Psychiatry, 2018, 8(1), 117.
[http://dx.doi.org/10.1038/s41398-018-0162-2] [PMID: 29907742]
[82]
Jiménez-Jiménez, F.J.; Tejeiro, J.; Martínez-Junquera, G.; Cabrera-Valdivia, F.; Alarcón, J.; García-Albea, E. Parkinsonism exacerbated by paroxetine. Neurology, 1994, 44(12), 2406.
[http://dx.doi.org/10.1212/WNL.44.12.2406] [PMID: 7991139]
[83]
Simons, J.A. Fluoxetine in Parkinson’s disease. Mov. Disord., 1996, 11(5), 581-582.
[http://dx.doi.org/10.1002/mds.870110517] [PMID: 8866503]
[84]
Wermuth, L.; Sorensen, P.S.; Timm, B.; Utzon, N.P.; Boas, J.; Dupont, E.; Magnussen, I.; Mikkelsen, B.; Worm-Petersen, J.; Lauritzen, L.; Bayer, L.; Bech, P. Depression in idiopathic Parkinson’s disease treated with citalopram-a placebo-controlled trial Nordic. J. Psychiatry, 1998, 52(2), 163-169.
[http://dx.doi.org/10.1080/08039489850139049]
[85]
Avila, A.; Cardona, X.; Martin-Baranera, M.; Maho, P.; Sastre, F.; Bello, J. Does nefazodone improve both depression and Parkinson disease? A pilot randomized trial. J. Clin. Psychopharmacol., 2003, 23(5), 509-513.
[http://dx.doi.org/10.1097/01.jcp.0000088908.24613.db] [PMID: 14520130]
[86]
Werneck, A.L.; Rosso, A.L.; Vincent, M.B. The use of an antagonist 5-HT2a/c for depression and motor function in Parkinson’ disease. Arq. Neuropsiquiatr., 2009, 67(2B), 407-412.
[http://dx.doi.org/10.1590/s0004-282x2009000300007] [PMID: 19623435]
[87]
Antonini, A.; Tesei, S.; Zecchinelli, A.; Barone, P.; De Gaspari, D.; Canesi, M.; Sacilotto, G.; Meucci, N.; Mariani, C.; Pezzoli, G. Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson’s disease and depression: Effect on quality of life. Mov. Disord., 2006, 21(8), 1119-1122.
[http://dx.doi.org/10.1002/mds.20895] [PMID: 16637039]
[88]
Devos, D.; Dujardin, K.; Poirot, I.; Moreau, C.; Cottencin, O.; Thomas, P.; Destée, A.; Bordet, R.; Defebvre, L. Comparison of desipramine and citalopram treatments for depression in Parkinson’s disease: A double-blind, randomized, placebo-controlled study. Mov. Disord., 2008, 23(6), 850-857.
[http://dx.doi.org/10.1002/mds.21966] [PMID: 18311826]
[89]
Menza, M.; Dobkin, R.D.; Marin, H.; Mark, M.H.; Gara, M.; Buyske, S.; Bienfait, K.; Dicke, A. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology, 2009, 72(10), 886-892.
[http://dx.doi.org/10.1212/01.wnl.0000336340.89821.b3] [PMID: 19092112]
[90]
Richard, I.H.; McDermott, M.P.; Kurlan, R.; Lyness, J.M.; Como, P.G.; Pearson, N.; Factor, S.A.; Juncos, J.; Serrano Ramos, C.; Brodsky, M.; Manning, C.; Marsh, L.; Shulman, L.; Fernandez, H.H.; Black, K.J.; Panisset, M.; Christine, C.W.; Jiang, W.; Singer, C.; Horn, S.; Pfeiffer, R.; Rottenberg, D.; Slevin, J.; Elmer, L.; Press, D.; Hyson, H.C.; McDonald, W. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology, 2012, 78(16), 1229-1236.
[http://dx.doi.org/10.1212/WNL.0b013e3182516244] [PMID: 22496199]
[91]
Rektorová, I.; Rektor, I.; Bares, M.; Dostál, V.; Ehler, E.; Fanfrdlová, Z.; Fiedler, J.; Klajblová, H.; Kulist’ák, P.; Ressner, P.; Svátová, J.; Urbánek, K.; Velísková, J. Pramipexole and pergolide in the treatment of depression in Parkinson’s disease: a national multicentre prospective randomized study. Eur. J. Neurol., 2003, 10(4), 399-406.
[http://dx.doi.org/10.1046/j.1468-1331.2003.00612.x] [PMID: 12823492]
[92]
Navan, P.; Findley, L.J.; Jeffs, J.A.; Pearce, R.K.; Bain, P.G. Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson’s disease. Mov. Disord., 2003, 18(2), 176-180.
[http://dx.doi.org/10.1002/mds.10320] [PMID: 12539211]
[93]
Barone, P.; Poewe, W.; Albrecht, S.; Debieuvre, C.; Massey, D.; Rascol, O.; Tolosa, E.; Weintraub, D. Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol., 2010, 9(6), 573-580.
[http://dx.doi.org/10.1016/S1474-4422(10)70106-X] [PMID: 20452823]
[94]
Smith, K.M.; Eyal, E.; Weintraub, D. Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability. JAMA Neurol., 2015, 72(1), 88-95.
[http://dx.doi.org/10.1001/jamaneurol.2014.2472] [PMID: 25420207]
[95]
Barone, P.; Santangelo, G.; Morgante, L.; Onofrj, M.; Meco, G.; Abbruzzese, G.; Bonuccelli, U.; Cossu, G.; Pezzoli, G.; Stanzione, P.; Lopiano, L.; Antonini, A.; Tinazzi, M. A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson’s disease patients. Eur. J. Neurol., 2015, 22(8), 1184-1191.
[http://dx.doi.org/10.1111/ene.12724] [PMID: 25962410]
[96]
Shabnam, G.N.; Th, C.; Kho, D. H, R.; Ce, C. Therapies for depression in Parkinson’s disease. Cochrane Database Syst. Rev., 2003, (3)CD003465
[PMID: 12917968]
[97]
Weintraub, D.; Morales, K.H.; Moberg, P.J.; Bilker, W.B.; Balderston, C.; Duda, J.E.; Katz, I.R.; Stern, M.B. Antidepressant studies in Parkinson’s disease: a review and meta-analysis. Mov. Disord., 2005, 20(9), 1161-1169.
[http://dx.doi.org/10.1002/mds.20555] [PMID: 15954137]
[98]
Rocha, F.L.; Murad, M.G.; Stumpf, B.P.; Hara, C.; Fuzikawa, C. Antidepressants for depression in Parkinson’s disease: systematic review and meta-analysis. J. Psychopharmacol. (Oxford), 2013, 27(5), 417-423.
[http://dx.doi.org/10.1177/0269881113478282] [PMID: 23427193]
[99]
Skapinakis, P.; Bakola, E.; Salanti, G.; Lewis, G.; Kyritsis, A.P.; Mavreas, V. Efficacy and acceptability of selective serotonin reuptake inhibitors for the treatment of depression in Parkinson’s disease: a systematic review and meta-analysis of randomized controlled trials. BMC Neurol., 2010, 10, 49.
[http://dx.doi.org/10.1186/1471-2377-10-49] [PMID: 20565960]
[100]
Troeung, L.; Egan, S.J.; Gasson, N. A meta-analysis of randomised placebo-controlled treatment trials for depression and anxiety in Parkinson’s disease. PLoS One, 2013, 8(11)e79510
[http://dx.doi.org/10.1371/journal.pone.0079510] [PMID: 24236141]
[101]
da Silva, T.M.; Munhoz, R.P.; Alvarez, C.; Naliwaiko, K.; Kiss, A.; Andreatini, R.; Ferraz, A.C. Depression in Parkinson’s disease: a double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation. J. Affect. Disord., 2008, 111(2-3), 351-359.
[http://dx.doi.org/10.1016/j.jad.2008.03.008] [PMID: 18485485]
[102]
Leo, R.J. Movement disorders associated with the serotonin selective reuptake inhibitors. J. Clin. Psychiatry, 1996, 57(10), 449-454.
[http://dx.doi.org/10.4088/JCP.v57n1002] [PMID: 8909330]
[103]
Cole, K.; Vaughan, F.L. The feasibility of using cognitive behaviour therapy for depression associated with Parkinson’s disease: a literature review. Parkinsonism Relat. Disord., 2005, 11(5), 269-276.
[http://dx.doi.org/10.1016/j.parkreldis.2005.03.002] [PMID: 15970452]
[104]
Oehlberg, K.; Barg, F.K.; Brown, G.K.; Taraborelli, D.; Stern, M.B.; Weintraub, D. Attitudes regarding the etiology and treatment of depression in Parkinson’s disease: a qualitative study. J. Geriatr. Psychiatry Neurol., 2008, 21(2), 123-132.
[http://dx.doi.org/10.1177/0891988708316862] [PMID: 18474721]
[105]
Veazey, C.; Aki, S.O.; Cook, K.F.; Lai, E.C.; Kunik, M.E. Prevalence and treatment of depression in Parkinson’s disease. J. Neuropsychiatry Clin. Neurosci., 2005, 17(3), 310-323.
[http://dx.doi.org/10.1176/jnp.17.3.310] [PMID: 16179652]
[106]
Frisina, P.G.; Borod, J.C.; Foldi, N.S.; Tenenbaum, H.R. Depression in Parkinson’s disease: health risks, etiology, and treatment options. Neuropsychiatr. Dis. Treat., 2008, 4(1), 81-91.
[PMID: 18728814]
[107]
Gupta, R. Treatment of depression in an elderly Asian Indian male: a cognitive behavioural approach. Clin. Gerontol., 2000, 22(1), 87-90.
[108]
Heinrichs, N.; Hoffman, E.C.; Hofmann, S.G. Cognitive-behavioral treatment for social phobia in Parkinson’s disease: A single-case study. Cognit. Behav. Pract., 2001, 8(4), 328-335.
[http://dx.doi.org/10.1016/S1077-7229(01)80005-5] [PMID: 16770438]
[109]
Feeney, F.; Egan, S.; Gasson, N. Treatment of depression and anxiety in Parkinson’s disease: a pilot study using group cognitive behavioural therapy. Clin. Psychol., 2005, 9(1), 31-38.
[http://dx.doi.org/10.1080/13284200500048240]
[110]
Dobkin, R.D.; Allen, L.A.; Menza, M. A cognitive-behavioral treatment package for depression in Parkinson’s disease. Psychosomatics, 2006, 47(3), 259-263.
[http://dx.doi.org/10.1176/appi.psy.47.3.259] [PMID: 16684945]
[111]
Farabaugh, A.; Locascio, J.J.; Yap, L.; Growdon, J.; Fava, M.; Crawford, C.; Matthews, J.; McCutchen, J.; Buchin, J.; Pava, J.; Alpert, J.E. Cognitive-behavioral therapy for patients with Parkinson’s disease and comorbid major depressive disorder. Psychosomatics, 2010, 51(2), 124-129.
[http://dx.doi.org/10.1176/appi.psy.51.2.124] [PMID: 20332287]
[112]
Mohlman, J.; Reel, D.H.; Chazin, D.; Ong, D.; Georgescu, B.; Tiu, J.; Dobkin, R.D. A novel approach to treating anxiety and enhancing executive skills in an older adult with Parkinson’s disease. Clin. Case Stud., 2010, 9(1), 74-90.
[http://dx.doi.org/10.1177/1534650109351305] [PMID: 20419071]
[113]
Dobkin, R.D.; Menza, M.; Allen, L.A.; Gara, M.A.; Mark, M.H.; Tiu, J.; Bienfait, K.L.; Friedman, J. Cognitive-behavioral therapy for depression in Parkinson’s disease: a randomized, controlled trial. Am. J. Psychiatry, 2011, 168(10), 1066-1074.
[http://dx.doi.org/10.1176/appi.ajp.2011.10111669] [PMID: 21676990]
[114]
Dobkin, R.D.; Rubino, J.T.; Allen, L.A.; Friedman, J.; Gara, M.A.; Mark, M.H.; Menza, M. Predictors of treatment response to cognitive-behavioral therapy for depression in Parkinson’s disease. J. Consult. Clin. Psychol., 2012, 80(4), 694-699.
[http://dx.doi.org/10.1037/a0027695] [PMID: 22409644]
[115]
Lewinsohn, P.M.; Clarke, G.N. Psychosocial treatments for adolescent depression. Clin. Psychol. Rev., 1999, 19(3), 329-342.
[http://dx.doi.org/10.1016/S0272-7358(98)00055-5] [PMID: 10097874]
[116]
Oei, T.P.; Dingle, G. The effectiveness of group cognitive behaviour therapy for unipolar depressive disorders. J. Affect. Disord., 2008, 107(1-3), 5-21.
[http://dx.doi.org/10.1016/j.jad.2007.07.018] [PMID: 17716745]
[117]
Dobkin, R.D.; Allen, L.A.; Menza, M. Cognitive-behavioral therapy for depression in Parkinson’s disease: a pilot study. Mov. Disord., 2007, 22(7), 946-952.
[http://dx.doi.org/10.1002/mds.21455] [PMID: 17377926]
[118]
Troeung, L.; Egan, S.J.; Gasson, N. A waitlist-controlled trial of group cognitive behavioural therapy for depression and anxiety in Parkinson’s disease. BMC Psychiatry, 2014, 14, 19.
[http://dx.doi.org/10.1186/1471-244X-14-19] [PMID: 24467781]
[119]
Veazey, C.; Cook, K.F.; Stanley, M.; Lai, E.C.; Kunik, M.E. Telephone-administered cognitive behavioral therapy: a case study of anxiety and depression in Parkinson’s disease. J. Clin. Psychol. Med. Settings, 2009, 16(3), 243-253.
[http://dx.doi.org/10.1007/s10880-009-9167-6] [PMID: 19404724]
[120]
Sproesser, E.; Viana, M.A.; Quagliato, E.M.; de Souza, E.A. The effect of psychotherapy in patients with PD: A controlled study. Parkinsonism Relat. Disord., 2010, 16(4), 298-300.
[http://dx.doi.org/10.1016/j.parkreldis.2009.08.008] [PMID: 19864172]
[121]
Ryan, M.; Eatmon, C.V.; Slevin, J.T. Drug treatment strategies for depression in Parkinson disease. Expert Opin. Pharmacother., 2019, 20(11), 1351-1363.
[http://dx.doi.org/10.1080/14656566.2019.1612877] [PMID: 31120798]
[122]
Haasum, Y.; Fastbom, J.; Johnell, K. Use of antidepressants in Parkinson’s disease: A Swedish register-based study of over 1.5 million older people. Parkinsonism Relat. Disord., 2016, 27, 85-88.
[http://dx.doi.org/10.1016/j.parkreldis.2016.04.015] [PMID: 27117031]
[123]
Marsh, L. Depression and Parkinson’s disease: current knowledge. Curr. Neurol. Neurosci. Rep., 2013, 13(12), 409.
[http://dx.doi.org/10.1007/s11910-013-0409-5] [PMID: 24190780]
[124]
Mills, K.A.; Greene, M.C.; Dezube, R.; Goodson, C.; Karmarkar, T.; Pontone, G.M. Efficacy and tolerability of antidepressants in Parkinson’s disease: A systematic review and network meta-analysis. Int. J. Geriatr. Psychiatry, 2018, 33(4), 642-651.
[http://dx.doi.org/10.1002/gps.4834] [PMID: 29235150]
[125]
Dobkin, R.D.; Menza, M.; Bienfait, K.L.; Gara, M.; Marin, H.; Mark, M.H.; Dicke, A.; Friedman, J. Depression in Parkinson’s disease: symptom improvement and residual symptoms after acute pharmacologic management. Am. J. Geriatr. Psychiatry, 2011, 19(3), 222-229.
[http://dx.doi.org/10.1097/JGP.0b013e3181e448f7] [PMID: 20808132]
[126]
Whitlock, M.E.; Woodward, P.W.; Alexander, R.C. Is high placebo response really a problem in depression trials? A critical re-analysis of depression studies. Innov. Clin. Neurosci., 2019, 16(7-08), 12-17.
[PMID: 31832258]
[127]
Li, F.; Nasir, M.; Olten, B.; Bloch, M.H. Meta-analysis of placebo response in adult antidepressant trials. CNS Drugs, 2019, 33(10), 971-980.
[http://dx.doi.org/10.1007/s40263-019-00662-y] [PMID: 31573058]
[128]
Barone, P. Treatment of depressive symptoms in Parkinson’s disease. Eur. J. Neurol., 2011, 18(Suppl. 1), 11-15.
[http://dx.doi.org/10.1111/j.1468-1331.2010.03325.x] [PMID: 21255198]
[129]
Chung, S.J.; Asgharnejad, M.; Bauer, L.; Ramirez, F.; Jeon, B. Evaluation of rotigotine transdermal patch for the treatment of depressive symptoms in patients with Parkinson’s disease. Expert Opin. Pharmacother., 2016, 17(11), 1453-1461.
[http://dx.doi.org/10.1080/14656566.2016.1202917] [PMID: 27322571]

Rights & Permissions Print Cite
Article Metrics
40
1
World Autism Awareness Day
© 2024 Bentham Science Publishers | Privacy Policy